51,216 Shares in Benitec Biopharma Inc. (NASDAQ:BNTC) Acquired by Simplify Asset Management Inc.

Simplify Asset Management Inc. purchased a new position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 51,216 shares of the biotechnology company’s stock, valued at approximately $358,000. Simplify Asset Management Inc. owned 0.55% of Benitec Biopharma as of its most recent SEC filing.

Separately, GAMMA Investing LLC grew its holdings in Benitec Biopharma by 53.0% during the 2nd quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 1,884 shares in the last quarter. 52.19% of the stock is owned by hedge funds and other institutional investors.

Benitec Biopharma Stock Performance

Shares of BNTC opened at $8.63 on Friday. The firm has a fifty day simple moving average of $8.96 and a 200 day simple moving average of $7.71. Benitec Biopharma Inc. has a 12 month low of $2.69 and a 12 month high of $10.88. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $80.80 million, a price-to-earnings ratio of -4.70 and a beta of 0.90.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Guggenheim assumed coverage on Benitec Biopharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $17.00 target price on the stock. Leerink Partners began coverage on shares of Benitec Biopharma in a research report on Monday, July 22nd. They issued an “outperform” rating and a $13.00 target price for the company. Piper Sandler started coverage on Benitec Biopharma in a research note on Thursday, June 13th. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Leerink Partnrs raised shares of Benitec Biopharma to a “strong-buy” rating in a research report on Monday, July 22nd. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $19.00.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.